Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 + HX008 in Advanced Melanoma
NCT04616443Phase 2Recruiting
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Nov 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of OH2 in melanoma, sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd.. Started Dec 2020; status: recruiting.
02
Drugs
OH2
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04616443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616443.